Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 3
2011 6
2012 3
2014 3
2015 2
2017 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
MicroRNAs: tools for cancer diagnostics.
Paranjape T, Slack FJ, Weidhaas JB. Paranjape T, et al. Gut. 2009 Nov;58(11):1546-54. doi: 10.1136/gut.2009.179531. Gut. 2009. PMID: 19834118 Free PMC article.
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.
McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. McVeigh TP, et al. Among authors: paranjape t. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. Cell Cycle. 2015. PMID: 25961464 Free PMC article.
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Pelletier C, et al. Among authors: paranjape t. Cell Cycle. 2011 Jan 1;10(1):90-9. doi: 10.4161/cc.10.1.14359. Epub 2011 Jan 1. Cell Cycle. 2011. PMID: 21191178 Free PMC article.
A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. Smits KM, et al. Among authors: paranjape t. Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12. Clin Cancer Res. 2011. PMID: 21994416 Free PMC article.
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. Ratner E, et al. Among authors: paranjape t. Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647319 Free PMC article.
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. Chung CH, et al. Among authors: paranjape t. Ann Oncol. 2014 Nov;25(11):2230-2236. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31. Ann Oncol. 2014. PMID: 25081901 Free PMC article. Clinical Trial.
17 results